Graf Akcie BLCM (Bellicum Pharmaceuticals Inc). Diskuze k akciím BLCM. Aktuální informace BLCM.

Základní informace o společnosti Bellicum Pharmaceuticals Inc (Akcie BLCM)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 22.93M
Hodnota podniku (EV) N/A
Tržby 1.2M
EBITDA N/A
Zisk 4.427M
Růst v tržbách Q/Q N/A %
Růst v tržbách Y/Y N/A %
P/E (Cena vůči ziskům) 1.13
Forward P/E -0.09
EV/Sales 5.18
EV/EBITDA N/A
EV/EBIT 0.78
PEG N/A
Price/Sales 19.10
P/FCF N/A
Price/Book -9.18
Účetní hodnota na akcii -0.29
Hotovost na akcii 4.34
FCF vůči ceně -183.04 %
Počet zaměstnanců 16
Tržba na zaměstnance 75.000k
Profit margin -1,544.40 %
Operating margin -3,494.42 %
Gross margin 100.00 %
EBIT margin 445.25 %
EBITDA margin -1,536.29 %
EPS - Zisk na akcii 2.39
EPS - Kvartální růst -97.43 %
EPS - Očekávaný růst příští rok -83.98 %
Return on assets 11.31 %
Return on equity -22.81 %
ROIC -8.63 %
ROCE 140.02 %
Dluhy/Equity -10.03
Čistý dluh/EBITDA 2.00
Current ratio 1.19
Quick Ratio 1.19
Volatilita 5.86
Beta 0.97
RSI 39.70
Cílová cena analytiků 5
Známka akcie (dle analytiků) 2.33
Insider ownership 0.59 %
Institutional ownership 21.55 %
Počet akcií 8.398M
Procento shortovaných akcií 12.84 %
Short ratio 6.26 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2014
Země United States

Finanční výsledky akcie BLCM

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$7.143$1.12$0.185$0.388$0.282$1.78$1.941$1.47
Cost Of Goods Sold--------
Gross Profit$7.143$1.12$0.185$0.388$0.282$1.78$1.941$1.47
Research And Development Expenses$64.535$71.588$65.663$51.263$33.561$12.071$7.899$5.796
SG&A Expenses$29.972$24.998$21.045$16.925$12.672$4.335$1.964$1.943
Other Operating Income Or Expenses--$-0.864$-0.58$-3.184---
Operating Expenses$94.507$96.586$87.572$68.768$49.417$59.618$9.863$7.739
Operating Income$-87.364$-95.466$-87.387$-68.38$-49.135$-57.838$-7.922$-6.269
Total Non-Operating Income/Expense$-25.113$-2.57$-4.392$-0.861$0.587$-26.127$-0.047$0.006
Pre-Tax Income$-112.477$-98.036$-91.779$-69.241$-48.548$-83.965$-7.969$-6.263
Income Taxes--------
Income After Taxes$-112.477$-98.036$-91.779$-69.241$-48.548$-83.965$-7.969$-6.263
Other Income--------
Income From Continuous Operations$-112.477$-98.036$-91.779$-69.241$-48.548$-83.965$-7.969$-6.263
Income From Discontinued Operations--------
Net Income$-112.477$-98.036$-91.779$-69.241$-48.548$-85.397$-9.062$-7.021
EBITDA$-77.199$-88.064$-82.849$-65.232$-47.457$-57.26$-7.43$-6.158
EBIT$-87.364$-95.466$-87.387$-68.38$-49.135$-57.838$-7.922$-6.269
Basic Shares Outstanding54333000
Shares Outstanding54333000
Basic EPS$-24.01$-24.37$-28.90$-25.70$-18.40$-340.40$-50.50$-42.60
EPS - Earnings Per Share$-24.01$-24.37$-28.90$-25.70$-18.40$-340.40$-50.50$-42.60
# 2020 2019 2018 2017 2016 2015
Current Ratio1.18476.02988.36216.98813.014153.1414
Long-term Debt / Capital1.21750.34410.2930.16130.0008-
Debt/Equity Ratio-8.00910.52520.41480.21110.0009-
Gross Margin100100100100100100
Operating Margin-1223.072-8523.75-47236.21-17623.71-17423.76-3249.326
EBIT Margin-1223.072-8523.75-47236.21-17623.71-17423.76-3249.326
EBITDA Margin-1080.765-7862.857-44783.24-16812.37-16828.72-3216.854
Pre-Tax Profit Margin-1574.647-8753.214-49610.27-17845.62-17215.6-4717.135
Net Profit Margin-1574.646-8753.214-49610.27-17845.62-17215.6-4797.584
Asset Turnover0.06140.00920.00140.00290.00180.0091
Inventory Turnover Ratio------
Receiveable Turnover23.57431.23210.57811.16170.64095.9732
Days Sales In Receivables15.483296.2366631.3514314.201569.503561.1067
ROE - Return On Equity429.0225-143.1643-108.4243-71.6974-31.9359-43.8148
Return On Tangible Equity2368.435-143.1642-108.4243-71.6974-31.9359-43.8148
ROA - Return On Assets-96.7544-80.6874-67.7196-52.4406-30.2657-42.8844
ROI - Return On Investment-515.1934-93.9033-76.6582-60.1306-31.9111-43.8148
Book Value Per Share-0.948115.720425.431335.562756.444872.6637
Operating Cash Flow Per Share2.03174.4246-4.2974-5.156214.8499-186.0266
Free Cash Flow Per Share2.32237.8364-5.4322-5.7775215.9969-187.1933

Porovnání s konkurencí: Akcie BLCM

Společnost P/E PEG Růst v tržbách (roční) Růst v EPS Return on equity P/B Profit margin
BLCM 1.13 N/A N/A % -83.98 % -22.81 % -9.18 -1,544.40 %
Akcie ALIM 40.00 N/A 8.02 % 333.33 % -42.84 % -3.81 -10.51 %
Akcie ALDX 0.00 N/A N/A % 13.04 % -37.99 % 8.11 N/A %
Akcie INGN N/A 7.17 1.80 % 187.50 % -0.69 % 2.71 -1.89 %
Akcie TTOO 0.00 N/A 171.09 % 0.00 % -510.02 % 14.84 -258.12 %

Nedávné obchody insiderů: Akcie BLCM

Jméno Obchod Cena Objem
David M. Spencer
Chief Scientific Officer
Prodej
18 Jul 2018
$7.63 $305,200
David M. Spencer
Chief Scientific Officer
Prodej
4 Sep 2018
$7.04 $70,400
Jon P Stonehouse
Director
Nákup
9 Nov 2018
$4.56 $45,600
Richard A. Fair
President and CEO
Nákup
21 Aug 2019
$0.99 $19,800
Shane Ward
Sr VP and Chief Legal SO
Nákup
29 Aug 2019
$1.23 $9,840
Richard A. Fair
President and CEO
Nákup
10 Sep 2019
$1.25 $50,000
Jr Joseph Paul Woodard
SVP Clinical and Medical Affairs
Option
13 Nov 2019
$0.82 $3,075
Rosemary Y. Williams
Vice President, Finance, and PAO
Option
2 Jan 2020
$1.51 $3,115
Alan K. Smith
EVP and Technical Operations
Option
2 Jan 2020
$1.51 $5,900
Aaron E. Foster
Sr VP and Head of Research
Option
2 Jan 2020
$1.51 $4,719
Richard A. Fair
President and CEO
Nákup
17 Mar 2020
$4.00 $20,000

Diskuze k akciím BLCM